Leslie Williams has more than 25 years of industry experience in healthcare, management, commercial product development and marketing. In 2010 she founded ImmusanT, Inc., which subsequently acquired the assets of Melbourne, Australia based Nexpep. She has built and led the team since inception. In 2015 Williams received the Distinguished Alumni Achievement Award from the University of Iowa in recognition of her accomplishments in her professional life. Prior to founding ImmusanT, she was President & CEO of Ventaira Pharmaceuticals, which became a significant player in the pulmonary drug delivery market under her leadership. While President & CEO of Ventaira Pharmaceuticals, she was recognized as one of the top 100 leaders in life sciences by PharmaVOICE magazine.
Prior to Ventaira, Ms. Williams served as director of marketing for INO Therapeutics, Inc., where she played a significant role in the NDA submission for INOmax (nitric oxide) for inhalation, a drug for the treatment of pulmonary hypertension. Responsible for the commercial aspects of INOmax's US market introduction, from setting objectives and strategy to developing key constituency groups and expert advisory boards, as well as representing INO Therapeutics on Capitol Hill, Williams also assisted with expansion of the INO-therapy platform into the European marketplace. The company was acquired by Ikaria Holdings in 2007. Ms. Williams’ prior pharmaceutical industry experience includes commercial positions at Merck and GlaxoSmithKline, and drug-delivery and -monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.). She was a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A. She served on the Boards of Hepregen Corporation and CDI Bioscience. She currently serves on the Advisory Board of The Capital Network (TCN) and is on the Executive Board of the University of Iowa School of Pharmacy. She also serves on the Editorial Advisory Board of Life Science Leader as well as The Journal of Advanced Therapies and Medical Innovation Sciences. In addition, she serves as a mentor in the Boston University Kindle Program.
Ms. Williams holds an MBA from Washington University, John Olin School of Business, and a BS degree with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.